MiNK Therapeutics is making waves in the cell therapy landscape with its groundbreaking allogeneic invariant natural killer T ...
MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform ...
MiNK Therapeutics will announce Q1 2025 financial results on May 15, followed by a conference call at 8:30 a.m. ET. MiNK Therapeutics, Inc. announced that it will release its first quarter 2025 ...
MiNK Therapeutics, Inc. announced its first-quarter 2025 financial results and highlighted significant progress in its development of allogeneic invariant natural killer T (iNKT) cell therapies. The ...
Dr. Jennifer Buell: Thank you, Stephanie. Good morning, everyone. This quarter marks a defining period for MiNK Therapeutics, Inc. We are now a fully independent operated company focused, agile, and ...
Q4 2025 Management View Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, ...
Good morning, and welcome to MiNK Therapeutics' Second Quarter 2025 Conference Call and Webcast. [Operator Instructions] Please note that this event is being recorded. If anyone has any objections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results